Cosmebiome: Effects Of A Probiotic Formulation On Stress and Skin Health in Younger Adult Females

Sponsor
Lallemand Health Solutions (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT06057883
Collaborator
Laboratoire Cosderma (Other)
30
1
3

Study Details

Study Description

Brief Summary

The goal of this clinical trial is to test to efficacy of a probiotic blend on stress and skin appearance in young females. It is hypothesized that those taking the probiotic blend will have decreased levels of perceived stress and this will be reflected positively on their skin appearance.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Probiotic
Phase 2

Detailed Description

The goal of this open-label clinical trial is to evaluate the potential beneficial effects of a probiotic formulation on mental wellbeing and skin appearance in healthy young adult females in line with the holistic approach context and beauty from within principle. The main questions it aims to answer are related to:

  • Probiotics effects on stress.

  • Probiotics effects on sleep quality.

  • Probiotics effects on skin appearance (fine lines and skin tone) and parameters (hydration and firmness) Participants will be recruited and, if consenting and eligible, will be provided with the probiotic capsules and instructed to ingest one capsule daily, preferably in the evening for 56 consecutive days. In-person visits will take place at baseline, mid-intervention (Day 28), and end of intervention (Day 56) to carry out assessment activities at Cosderma site.

Researchers will compare the outcome assessment measures after the probiotic ingestion to baseline values to highlight any significant effects or trends.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
A Single Arm, Open-Label, and Proof-of-Concept StudyA Single Arm, Open-Label, and Proof-of-Concept Study
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Effects of Probiotics Formulation on Stress and Skin Health in Younger Adult Females: A Holistic Approach to Skin Health, an Open-Label Proof-of-Concept Study
Anticipated Study Start Date :
Sep 1, 2023
Anticipated Primary Completion Date :
Nov 1, 2023
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Probiotic arm

All participants will be given the active probiotic product as this is a single arm, open-label study.

Dietary Supplement: Probiotic
A blend of two probiotic strains. Participants will take 1 capsule daily at 3 billion Colony Forming Units (CFUs)

Outcome Measures

Primary Outcome Measures

  1. The effect of the probiotic intake on perceived stress levels. [56 Days]

    The change from baseline in the level of perceived stress will be assessed by the 10-item perceived stress scale (PSS-10) questionnaire before consumption of the probiotic (baseline) then after 28 and 56 days of intake. The PSS-10 is a widely used self-report questionnaire that measures the degrees to which individuals perceive their lives as unpredictable, uncontrollable, and overloaded. The scale consists of 10 items, which assess the individual's feelings and thoughts related to stress in the past month. The items are designed to capture both positive and negative aspects of stress, including factors such as feeling nervous or stressed, feeling confident in handling personal problems, and feeling that things are going well. The PSS-10 has been extensively used in research studies and clinical settings and has been found to have good reliability and validity.

Secondary Outcome Measures

  1. The effect of the probiotic intake on sleep quality. [56 Days]

    Participants will be asked to complete the 3-item questionnaire adapted from the Canadian Health Measures Survey before consumption of the probiotic (baseline) then after 28 and 56 days of intake. This is not a validated questionnaire; the questions were administered to assess subjective sleep quality among Canadians by Statistics Canada. For each item, the percentage of each answer will be calculated and compared to baseline at Day 28 (mid-intervention) and Day 56 (end of intervention).

  2. The effect of the probiotic intake on skin hydration. [56 Days]

    The hydration level of the upper layers of the epidermis will be assessed with the Corneometer CM825® which runs at frequencies between 0.9 and 1.2 MHz. The surface of measurement for the probe is 49 mm². The capacitance of the system (electrodes and upper skin layers) being influenced by the changes of the dielectric constant of the skin's surface, when the hydration level of the stratum corneum varies, the dielectric properties of this medium are modified and consequently the capacitance of the system is modified. The moisturizing effect will be evaluated by comparing measurements taken at baseline and after intervention (at 28 and 56 Days).

  3. The effect of the probiotic intake on skin firmness. [56 Days.]

    Skin firmness will be assessed by Cutometer®. The device generates a negative pressure which can vary between 20 up to 500 mbar. The zone of skin to be measured is sucked up in the opening of the probe by this pressure. The depth of penetration of the skin inside the opening of the probe is determined without contact, by an optical measurement system. This system is constituted by a transmitter and a receiver of light. Two opposite glass prisms transmit the light of the transmitter towards the receiver. The quantity of received light is proportional in the depth of penetration of the skin. The skin is sucked up inside the probe (diameter 2mm) for 2 seconds (phase of pursuit) with a constant negative pressure of 450 mbar. Then the pressure stops, and the skin returns to its initial state (phase of relaxation). values obtained at Day 28 and Day 56 twill be compared to baseline.

  4. The effect of the probiotic intake on facial fine lines appearance. [56 Days]

    Facial fine lines will be clinically assessed by an experienced technician on a 10-point scale. Assessment will take place on the whole face, forehead, and crow's feet area (0 = no visible fine lines, 9 = very visible fine lines). The clinical scoring consists of a visual assessment of the cutaneous state before and after intervention, in order to assess the evolution in skin appearance. For this purpose, the Technician sits the subject in front of the table Evalux bench® (Orion concept) with a long-life and calibrated lighting system (leds - 6500°K). The Technician turns on the 3 neon lights: 2 lateral and 1 horizontal. Score recorded at Day 28 and 56 will be compared to baseline.

  5. The effect of the probiotic intake on skin tone appearance. [56 Days]

    Facial skin tone will be clinically assessed by an experienced technician on a 10-point scale. Assessment will take place on uniformity (0 = Non-uniform complexion (roughness, visible skin texture, etc.), 9 = Very uniform complexion/homogeneous and regular skin surface, etc.), and radiance (0 = Non-glowy complexion (dull, heterogeneous complexion, irregular skin texture, grey veil, blurred skin), 9 = Glowy complexion (radiant, homogeneous, bright complexion, regular skin texture, light or bright complexion, looking very healthy)). The Technician sits the subject in front of the table Evalux bench® (Orion concept) with a long-life and calibrated lighting system (leds - 6500°K). The Technician turns on the 3 neon lights: 2 lateral and 1 horizontal, radiance assessment of the complexion. Score recorded at Day 28 and 56 will be compared to baseline.

  6. The effect of the probiotic intake on general skin appearance. [56 Days]

    Photographs of the front face and one profile will be taken by Visia-CR® camera. Images will be taken at two settings standard and polarized light. Standard light: Flat lighting provides even, white light across the entire image with a minimum of highlight and shadow. age 4 (standard 4: Raking top light) = Strong white light coming from the top of the booth. Polarized light source with a perpendicularly oriented polarizer over the lens. This filters out surface reflections for superior visualization of sub-surface detail (vascular lesions, pigment, etc.). All images will be sent to the Sponsor. No statistical analysis will be performed. Picture will be used for illustrative purpose only.

  7. Overall participants' satisfaction with the intervention. [56 Days]

    Participants will be asked to complete a self-administered questionnaire designed to assess participant's satisfaction with the product after 28 and 56 days of intake. This questionnaire is written by Cosderma in collaboration with the Sponsor. The answering modalities will be the following: "strongly agree", "somewhat agree", "somewhat disagree", "strongly disagree". A "Non-applicable" option will be added when needed.

  8. The effect of the probiotic intake on Gastro-Intestinal (GI) health. [56 Days.]

    Participants will be asked to complete the 15-item gastrointestinal symptom rating scale (GSRS) questionnaire before starting intervention (baseline) then after 28 and 56 days of intervention. GSRS is a widely used and validated tool. This self-administered questionnaire is designed to assess the frequency and severity of gastrointestinal (GI) symptoms. It consists of 15 items, which are grouped into five subscales: Abdominal pain Reflux syndrome Indigestion syndrome Diarrhea syndrome Constipation syndrome Average total scores at Day 28 (mid-intervention) and Day 56 (end of intervention) will be compared to baseline.

  9. The probiotic's safety and tolerability. [56 Days]

    Incidence of clinical events (sensations of discomfort or clinical signs) occurring during the study after the consumption of the probiotic.

Eligibility Criteria

Criteria

Ages Eligible for Study:
30 Years to 45 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
Each participant must fulfill all the inclusion criteria below:
  1. Females between 30 to 45 years old, inclusive.

  2. Caucasian type.

  3. Normal to dry skin to the face (excluded very dry skin).

  4. Have a regular menstrual cycle (participants not known to have hormonal imbalance, be in the pre-menopausal or menopausal state).

  5. Have a skin phototype I, II or III.

  6. Have a negative urine pregnancy test at screening and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months, and participants must agree to sign a release form (Appendix 4).

Other acceptable methods of birth control include:
  • Abstinence or agrees to use contraception if planning to become sexually active

  • Hormonal contraceptives

  • Double-barrier method

  • Intrauterine devices

  • Non-heterosexual lifestyle

  • Vasectomy of partner at least 6 months prior to screening

  1. Able to give free, informed and express consent to participate,

  2. Affiliated with social security in accordance with the recommendations of the French law (Loi Jardé: n° 2016-1537 - 16.11.16) concerning biomedical research.

  3. Visible fine to moderate fine lines on at least one area of the face (e.g., forehead, or crow's feet area, etc.) as assessed by a score ≥ 2 and ≤ 6 on a 10-point clinical scale.

  4. Corneometer® on the face as assessed by an index > 20 and ≤ 60.

  5. Corneometer® on the forearms as assessed by an index ≤ 50.

  6. 50% of the participants fulfilling all inclusion criteria and, in addition, self-reported having a sensitive skin.

  7. Does not plan to expose face to sunlight during the study.

  8. Willingness to maintain eating habits for the duration of the study (quick check of diet: sugar/protein/fat/fruit intake and average drink consumption).

  9. Willing to refrain from using any cream and/or makeup on the face, eyes, lips, or palms for study visits and photo capture.

  10. Participants are otherwise healthy and in a good general health and mental health.

  11. Willing to discontinue consumption of probiotic supplements, probiotic fortified products, and fiber supplements for the duration of the study.

  12. Willingness to maintain the same skin care routine for the duration of the study.

  13. Willingness to complete all study visits, assessment questionnaires, and diaries.

Exclusion Criteria:
Eligible participants must not meet any of the non-inclusion criteria below:
  1. Currently pregnant, or breast feeding, or planning to be pregnant during the study.

  2. Current smoker.

  3. Suffering from a chronic or acute skin condition on the face and forearms (atopic dermatitis, acne, eczema, psoriasis, rash, severe dryness, etc.), unless the condition is deemed stabilized and will not affect study outcomes or be negatively affected by the intervention in the opinion of the investigator.

  4. Current use of antiaging products, unless the participant has been using the same product, with the same frequency and concentration for the past ≥ 3 months.

  5. Introduction of a new antiaging product during the study, or a change in the frequency or concentration of a routinely used antiaging product.

  6. Introduction of new skin care products during the study, unless medically prescribed.

  7. Facial surgery 5 years before study start.

  8. Chemical treatment (e.g., Botox injection) within 1 year before study start.

  9. Frequent UV exposure or expect high exposure to the sun during the study.

  10. Diagnosed with a general physical or mental health problem (e.g., diabetes, peptic ulcer, inflammatory bowel disease, depression, anxiety, insomnia, etc.) or systemic disease that may pose a safety risk, interfere with the dietary intake of the investigational product, or impact the assessment of study outcomes.

  11. Diagnosed with an autoimmune disease or are immune compromised due to medical condition or medications intake (e.g., acquired immunodeficiency (HIV), organ transplant, lymphoma, chemotherapy, chronic corticosteroids intake, etc.).

  12. Currently taking oral or local anti-inflammatory treatment or have been taken daily anti-inflammatory therapy in the 2 weeks preceding the inclusion visit. Note: participants could be eligible to participate after a 2-week washout period.

  13. Currently on corticosteroid treatment or antihistamines or other dermatological treatment or specialties based on vitamin A acid or its derivatives in the 2 weeks preceding the study. Note: participants could be eligible to participate after a 2-week washout period.

  14. Treated with an oral retinoid within 6 months prior to the study.

  15. Subjects who have applied make-up products to the face and forearms the day of the inclusion visit.

  16. Subjects who have washed their face and forearms with any other means than clear water (no soap or cleanser) on the day of the inclusion visit.

  17. Applied self-tanning products to the face and forearms within 2 weeks preceding the inclusion visit. Note: participants could be eligible to participate after a 2-week washout period.

  18. Have eyelashes extensions.

  19. Applied a moisturizing product (hygiene moisturizing product or care product) on the face and forearms within the last 48 hours.

  20. Wearing tight clothing that do not let the forearms show.

  21. Performed hair removal on the forearms within the last 48 hours.

  22. Have cutaneous marks on the face and forearms which could interfere with the skin's clinical signs assessment (pigmentation issues, scar tissues, over-developed hairiness, too many ephelides and naevi, sunburns, tattoos, etc.).

  23. Currently using a supplement that could affect study outcomes such as melatonin.

  24. Use of probiotics other than the study supplement within 1 month of the inclusion visit. Note: participants could be eligible to participate after a 4-week washout period.

  25. Use of any antibiotic drug within 1 month of the inclusion visit. Note: participants could be eligible to participate after a 4-week washout period.

  26. Subjects working as staff at Cosderma.

  27. Intending to be vaccinated during the study period.

  28. Currently enrolled or intending to be enrolled in another trial during the study period, or not meeting their 2 weeks exclusion period since their last participation in a study.

  29. Subjects who have been deprived of their liberty by administrative or legal decision or under judicial supervision.

  30. Subjects who could not be contacted in an emergency by phone.

  31. Milk or soy allergy or severe lactose intolerance.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Lallemand Health Solutions
  • Laboratoire Cosderma

Investigators

  • Principal Investigator: Brigitte Milpied, Laboratoire Cosderma

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Lallemand Health Solutions
ClinicalTrials.gov Identifier:
NCT06057883
Other Study ID Numbers:
  • L-028
First Posted:
Sep 28, 2023
Last Update Posted:
Sep 28, 2023
Last Verified:
Sep 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Lallemand Health Solutions

Study Results

No Results Posted as of Sep 28, 2023